Navigation Links
New Study Shows Efficacy of AROMASIN on Early Breast Cancer

New data from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-33 study, presented today at the San Antonio Breast Cancer Symposium, showed that// postmenopausal women with hormone receptor-positive breast cancer who received Aromasin after five years of tamoxifen were 56% less likely to have a relapse of breast cancer than those who received placebo (P=0.004).

“Aromasin provided patients with improved relapse-free survival despite early study closure, unblinding and crossover in the placebo arm,” said Dr. Terry Mamounas, NSABP breast committee chairman and lead investigator for the B-33 study. Median follow-up of 30 months also showed that disease-free survival was improved by 32% (P=0.07). Toxicity experienced with Aromasin in the B-33 trial was acceptable for the adjuvant setting.

These results continue to add to the body of evidence supporting the use of Aromasin after tamoxifen. According to Professor Charles Coombes, lead investigator for the landmark Intergroup Exemestane Study (IES) and director of cancer medicine, Imperial College, London, “Results from the IES show a clear benefit for women who receive Aromasin after two to three years of tamoxifen. The B-33 study results presented today show that Aromasin is also effective in the extended adjuvant setting after five years of tamoxifen.”

About B-33

The B-33 trial was a randomized, placebo-controlled, double-blind trial open to hormone receptor-positive breast cancer patients who were breast cancer free, having completed about five years of tamoxifen therapy – the standard treatment at the time of the start of the trial. Patients were randomly assigned to receive either exemestane or placebo for two years, which was later extended to five years in order to assess the clinical benefits of using Aromasin in the extended adjuvant setting.

Accrual of the B-33 study stopped in October 2003, after disclosure of results from the
'"/>




Page: 1 2 3 4

Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Study Shows Efficacy AROMASIN Early Breast Cancer

(Date:7/28/2014)... controlling red blood cell development have spread from Africa ... to a new study led by King,s College London. ... to look for the origin of changes in a ... adulthood. Fetal haemoglobin is normally found in fetuses and ... are able to keep making it as adults experience ...
(Date:7/28/2014)... NAPW honors Pamela ... Center, as a 2014 Professional Woman of the Year. ... leadership in community health. As the largest, most-recognized networking ... industry and profession, the National Association of Professional Women ... 600,000 members and nearly 300 Local Chapters. , In ...
(Date:7/28/2014)... 2014 Evolve Medical Clinics opened its first ... members virtual visits and dramatic operational changes that are set ... state that as many as 70% of all primary and ... to leave your office or home for a throat infection, ... cholesterol,” CEO and Founder Michael R. Freedman, MD said. “Doctor’s ...
(Date:7/28/2014)... The “Tissue Diagnostics Market by ... & Workflow, Special Staining), Disease (Breast Cancer, ... Cell Lung Cancer and Others), Product (Instruments ... Laboratories, Contract Research Organizations and Others) & ... & RoW) - Trends & Forecast to ...
(Date:7/28/2014)... Dallas, Texas (PRWEB) July 29, 2014 ... provides key market data on the China Surgical ... of US dollars, volume (in units) and average ... RF Generators, Electrocautery Generators, Ultrasonic Generators and Argon ... company shares and distribution shares data for each ...
Breaking Medicine News(10 mins):Health News:Study tracks worldwide spread of beneficial blood cell gene variant 2Health News:Study tracks worldwide spread of beneficial blood cell gene variant 3Health News:National Association of Professional Women Announces Pamela A. Schulters, Head Nurse at Kings County Hospital Center, a 2014 Professional Woman of the Year 2Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 2Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 3Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 2Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 3Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 4
... rhinosinusitis – an often recurring combination of congestion, discolored ... quality of life. ,A group of 25 physicians ... the first clinical trial guidelines for researchers working to ... ,The U.S. Food and Drug Administration (FDA) has issued ...
... be overcome by a newly developed vaccine according to ... funds from the government, said that their vaccine worked ... mice. This bacteria causes a range of potentially fatal ... ,Most hospital-acquired infections are commonly caused by it, causing ...
... convey the poisonous toxic meth chemicals to their unborn fetus ... Study. , ,Motherisk lab at the Hospital for Sick ... of adults and young children to gauge their exposure to ... from the expectant mother to the unborn child. ...
... Stern Review as a timely and authoritative reminder of ... world’s human population if the international community failed to ... prepared by former World Bank chief economist, Sir Nicholas ... Minister, Tony Blair, as the most important he has ...
... commonly prescribed invasive test performed during pregnancies in the ... them based on guidelines from the American College of ... studies and recommendations by the CDC that were based ... have suggested that amniocentesis increases the rate of miscarriage ...
... a recent research, an infant’s risk of cot death or ... defects that affect breathing and temperature control. // ... SIDS. The findings were published in the Journal of the ... these infants had flaws in their brainstem that affected the ...
Cached Medicine News:Health News:New Rhinosinusitis Clinical Trials Guidance Developed 2Health News:Vaccine may overcome Common Infections: Researchers 2Health News:A Timely Reminder Of Devastating Health Impact Of Climate Change 2Health News:Amniocentesis Safer for Pregnant Women 2Health News:Brain stem Defects associated with SIDS 2
(Date:7/28/2014)... July 28, 2014 STAAR Surgical Company (NASDAQ: ... marketer of implantable lenses and delivery systems for the ... results and conference call with investors to July 31, ... The Company rescheduled the release date and conference call ... for Hideo Watanabe , President of STAAR Japan, ...
(Date:7/28/2014)... SOUTH SAN FRANCISCO, Calif. , July 28, 2014 ... ) today provided an update on the status of ... KB001-A collaboration with Sanofi Pasteur.  ... has reached an agreement with Sanofi Pasteur to regain ... the collaboration and licensing agreement entered into in 2010 ...
(Date:7/28/2014)... July 28, 2014  Serco Inc., a provider ... Company has been awarded a re-compete contract to ... and its Deployable Medical Systems.  Serco will provide ... to provide world-class healthcare to meet warfighter and ... the globe. The five year contract has a ...
Breaking Medicine Technology:STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 3KaloBios Provides Update on KB001-A Partnership and Clinical Status 4KaloBios Provides Update on KB001-A Partnership and Clinical Status 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 6Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... and Non-Whites New to Antiretroviral Therapy Respond ... Similarly to ... treatment,regimens containing once-daily or twice-daily dosing of Abbott,s (NYSE:,ABT) protease ... (reducing the amount of HIV-1),and improving the immune system (increasing ...
... Tolerx, Inc., a,biopharmaceutical company engaged in the ... of immune-mediated diseases, announced today,that Genentech, a collaborator, ... anti-CD4 monoclonal antibody, into a phase 1 clinical ... is evaluating the,safety and tolerability of both single ...
Cached Medicine Technology:Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 4Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 5Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 6Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 7Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 8Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTC/1Q chairs are recommended for ... clean room, static control, health care ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With cast ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With cast ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
Medicine Products: